EZH2 in normal hematopoiesis and hematological malignancies
about
Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.Functional and therapeutic significance of EZH2 in urological cancersLong noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.Ezh2 promotes clock function and hematopoiesis independent of histone methyltransferase activity in zebrafish.Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.
P2860
Q33741100-9D008601-F966-44CF-993E-C0BB12F4D9D6Q33914244-35A8A6D4-5CC6-4F00-B2F2-FB07E804E1A4Q37437329-482E1E88-FE4A-42A8-8E62-4DF8E55D5488Q37517553-9BA8C4F2-53CB-44BB-A90A-176C6222801FQ37708968-98DC191F-B895-413C-BB04-05944F9F7084Q39340502-00580B19-D694-4053-B0F9-A23BF9229C35Q39379624-4C8B4551-8CB4-435A-A5E1-B20F1E1FECA1Q39457118-3CFED592-5554-4180-B56E-86AE47F53D50Q42321107-524F8A76-0D7A-46FA-833E-668E77E95940Q49977670-F8F43B91-5410-4A4E-AD00-93B8E50E5471Q50071606-199B647D-050C-428D-BB4C-0520352CDE38Q55018505-227E2983-CF5E-4FE6-A16E-E35323BCCA66
P2860
EZH2 in normal hematopoiesis and hematological malignancies
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
EZH2 in normal hematopoiesis and hematological malignancies
@ast
EZH2 in normal hematopoiesis and hematological malignancies
@en
EZH2 in normal hematopoiesis and hematological malignancies
@nl
type
label
EZH2 in normal hematopoiesis and hematological malignancies
@ast
EZH2 in normal hematopoiesis and hematological malignancies
@en
EZH2 in normal hematopoiesis and hematological malignancies
@nl
prefLabel
EZH2 in normal hematopoiesis and hematological malignancies
@ast
EZH2 in normal hematopoiesis and hematological malignancies
@en
EZH2 in normal hematopoiesis and hematological malignancies
@nl
P2860
P50
P921
P3181
P356
P1433
P1476
EZH2 in normal hematopoiesis and hematological malignancies
@en
P2093
Bernard Klein
Laurie Herviou
P2860
P304
P3181
P356
10.18632/ONCOTARGET.6198
P407
P5008
P577
2016-01-01T00:00:00Z